Latest News
- November 18, 2025ANDA application for Bimatoprost ophthalmic solution received Marketing Authorization from the USFDA!
- November 12, 2025ANDA application for Risperidone extended-release injectable suspension has received Marketing Authorization from the USFDA!
- October 30, 2025Accelerating Clinical Research!
- September 12, 2025Join CBCC at CPHI Frankfurt 2025
- August 08, 2025International Publication of Phase II clinical Trial
May 26, 2025
ANDA application for Paclitaxel Injection (Albumin bound) supported by CBCC has received Marketing Authorization from the USFDA
ANDA application for Paclitaxel Injection (Albumin bound) supported by CBCC has received Marketing Authorization from the USFDA
Type of Application: 505 (j)
Scope: End-to-end clinical trial management
Therapeutic Area: Oncology
Country of Trial Execution: India
CBCC Global Research: CHANGING LIVES THROUGH HOPE AND INNOVATION
Manoj Vyas
Dr. Sandeep Singh
Jaimeen Vanparia
Sanjeev Ganatra
Mark Kirschbaum
Nikhil Gandhi
Harakh Shah, PMP®
Tapan Shah
Kinnari Gandhi RQAP-GCP
Dr. Praveen Choudhary
Nikunj Patel
Ankit Parikh
Ajit Upadhyaya
Ankit Pandav
Devang Pandya
Jay Vyas
Udayan Vyas